JNJ-4680 / J&J - LARVOL DELTA

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=67 | Active, not recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Jun 2029 ➔ Nov 2027

Monotherapy • Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • ROS1

Initial results from a phase 1 study of an A2a receptor antagonist, administered as monotherapy and in combination with anti-PD1 therapy in patients with advanced non-small cell lung cancer (AACR 2025) - P1 | "JNJ-86974680 demonstrated a favorable safety and tolerability profile as monotherapy and in combination with cetrelimab, with dose-proportional PK and near-complete A2aR inhibition in peripheral lymphocytes at clinically relevant doses (15-30 mg). Ongoing dose escalation aims to optimize intratumoral drug concentrations and maximize A2aR inhibition."

Clinical • Combination therapy • First-in-human • IO biomarker • Metastases • Monotherapy • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ADORA2A

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=67 | Active, not recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Recruiting ➔ Active, not recruiting | N=126 ➔ 67

Enrollment change • Enrollment closed • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • ROS1

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Janssen Research & Development, LLC

New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • AR

Roswell Park Expert to Share Promising Results on New Immunotherapy Approach in Non-Small Cell Lung Cancer (PRWeb) - P1 | N=126 | NCT06116786 | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | "Prantesh Jain, MD, FACP...will share initial results of the study Tuesday during the 2025 annual meeting of the American Association for Cancer Research (AACR)....In part 1 of the study, which assessed safety and dose-finding, no dose-limiting toxicities were observed when JNJ-86974680 was administered alone or in combination with cetrelimab, an investigational PD-1 inhibitor. Among 41 patients with advanced NSCLC who had progressed on prior anti-PD-1 therapy, stable disease was the best overall response, with one patient remaining on treatment for more than eight months....The team found that JNJ-86974680 almost completely blocked A2a receptors in immune cells circulating in the blood. They hope that effect will increase as they determine the optimal dose and the drug concentrates inside the tumor."

P1 data • Non Small Cell Lung Cancer

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Johnson & Johnson Enterprise Innovation Inc. | N=76 ➔ 126 | Trial completion date: Aug 2028 ➔ Jun 2029

Enrollment change • Monotherapy • Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • ROS1